AHCT in Hodgkin's Disease
Autologous Hematopoietic Cell Transplantation in Hodgkin's Disease
Laura J. Johnston, Sandra J. Horning
Biology of Blood and Marrow Transplantation , Volume 6, Issue 3a, 2000.
Introduction
Hodgkin's disease (HD) is a neoplasm that was projected to afflict more than 7200 people in the U.S. in 1999 [1]. Although HD is associated with long-term survival after standard therapy in the majority of cases, a subset of patients eventually succumbs: 1300 patients were expected to die of HD in 1999. High-dose therapy (HDT) and autologous hematopoietic cell transplantation (AHCT) have been used in various settings in HD with the goal of prolonging disease-free survival (DFS) and overall survival (OS). This article will review the use of AHCT in HD, including pertinent clinical data, the source of stem cells, and preparative regimens with associated toxicities. We hope to impress on the reader the continued need for formal clinical trials to efficiently and correctly determine the role for AHCT in HD.
 6.3a.Johnston.pdf
 Copyright 1995-2010 - Carden Jennings Publishing Co., Ltd. All rights reserved. The material available at this site is for educational purposes only and is NOT intended for any diagnostic, clinically related, or other purpose. Carden Jennings Publishing Co., Ltd., assumes no responsibility for any use or misuse of this material and makes no warranty or representation of any kind with respect to the material available at this site.
|
|
